When a Merck & Co. in-house attorney recanted his deposition testimony in a patent brawl over Hepatitis C medications, Fish & Richardson lawyers knew they had an opening.
On the first day of trial in San Jose federal court, Merck revealed that its former patent prosecutor Philippe Durette would be disavowing the testimony. Instead he would admit that he sat in on a 2004 conference call with researchers from a Gilead predecessor who were developing the drug at issue in the trial. Durette was supposed to be “firewalled” from the discussion, because he was prosecuting Merck’s competing HCV patents.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
